| [1] Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482(7385):331-338.[2] Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121): 819-823.[3] Antoniani C, Romano O, Miccio A. Concise Review: Epigenetic Regulation of Hematopoiesis: Biological Insights and Therapeutic Applications. Stem Cells Transl Med. 2017; 6(12):2106-2114.[4] Dever DP, Porteus MH. The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation. Curr Opin Hematol. 2017;24(6):481-488.[5] He ZY, Men K, Qin Z, et al. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field. Sci China Life Sci. 2017;60(5):458-467.[6] Zuo E, Huo X, Yao X, et al. CRISPR/Cas9-mediated targeted chromosome elimination. Genome Biol. 2017;18(1):224.[7] Mettananda S, Gibbons RJ, Higgs DR. α-Globin as a molecular target in the treatment of β-thalassemia. Blood. 2015;125(24):3694-3701.[8] Mettananda S, Fisher CA, Hay D, et al. Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia. Nat Commun. 2017;8(1):424.[9] DeWitt MA, Magis W, Bray NL, et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci Transl Med. 2016;8(360): 360ra134.[10] Wen J, Tao W, Hao S, et al. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing. J Hematol Oncol. 2017;10(1):119.[11] Okura Y, Yamada M, Kuribayashi F, et al. Monocyte/ macrophage-specific NADPH oxidase contributes to antimicrobial host defense in X-CGD. J Clin Immunol. 2015; 35(2):158-167.[12] De Ravin SS, Li L, Wu X, et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci Transl Med. 2017;9(372):eaah 3480.[13] Gundry MC, Brunetti L, Lin A, et al. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. Cell Rep. 2016;17(5):1453-1461.[14] Mandal PK, Ferreira LM, Collins R, et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell. 2014;15(5):643-652.[15] Xu L, Yang H, Gao Y, et al. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo. Mol Ther. 2017;25(8): 1782-1789.[16] Peterson CW, Wang J, Norman KK, et al. Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates. Blood. 2016;127(20):2416-2426.[17] Bohaciakova D, Renzova T, Fedorova V, et al. An Efficient Method for Generation of Knockout Human Embryonic Stem Cells Using CRISPR/Cas9 System. Stem Cells Dev. 2017; 26(21):1521-1527.[18] Reimer J, Knöß S, Labuhn M, et al. CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo. Haematologica. 2017; 102(9):1558-1566.[19] Suzuki K, Tsunekawa Y, Hernandez-Benitez R, et al. In vivo genome editing via CRISPR/Cas9 mediated homology-I ndependent targeted integration. Nature. 2016;540(7631): 144-149.[20] Cai M, Yang Y. Targeted genome editing tools for disease modeling and gene therapy. Curr Gene Ther. 2014;14(1):2-9.[21] Tothova Z, Krill-Burger JM, Popova KD, et al. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell. 2017;21(4):547-555. e8.[22] Frascoli F, Kim PS, Hughes BD, et al. A dynamical model of tumour immunotherapy. Math Biosci. 2014;253:50-62.[23] Glass Z, Lee M, Li Y, et al. Engineering the Delivery System for CRISPR-Based Genome Editing. Trends Biotechnol. 2018; 36(2):173-185.[24] Liu C, Zhang L, Liu H, et al. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release. 2017;266:17-26.[25] Rothe M, Modlich U, Schambach A. Biosafety challenges for use of lentiviral vectors in gene therapy. Curr Gene Ther. 2013;13(6):453-468.[26] Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.[27] Heckl D, Kowalczyk MS, Yudovich D, et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol. 2014;32(9):941-946.[28] Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature. 2014;510(7504):235-240.[29] Pjechová M, Hernychová L, Tomašec P, et al. Adenoviral Vectors in Gene Therapy. Klin Onkol. 2015;28 Suppl 2: 2S75-80.[30] Ehrke-Schulz E, Schiwon M, Leitner T, et al. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes. Sci Rep. 2017;7(1):17113.[31] Petrs-Silva H, Linden R. Advances in recombinant adeno-associated viral vectors for gene delivery. Curr Gene Ther. 2013;13(5):335-345.[32] Dever DP, Bak RO, Reinisch A, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539(7629):384-389.[33] Song M. The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups. Biotechnol Prog. 2017;33(4):1035-1045.[34] Sum CH, Wettig S, Slavcev RA .Impact of DNA vector topology on non-viral gene therapeutic safety and efficacy. Curr Gene Ther. 2014;14(4):309-329.[35] He ZY, Men K, Qin Z, et al. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field. Sci China Life Sci. 2017;60(5):458-467.[36] Wang M, Zuris JA, Meng F, et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci U S A. 2016;113(11):2868-2873.[37] Miller JB, Zhang S, Kos P, et al. Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. Angew Chem Int Ed Engl. 2017;56(4):1059-1063.[38] D'Astolfo DS, Pagliero RJ, Pras A, et al. Efficient intracellular delivery of native proteins. Cell. 2015;161(3):674-690.[39] Yin H, Song CQ, Dorkin JR, et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016;34(3):328-333.[40] Dai WJ, Zhu LY, Yan ZY, et al. CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles. Mol Ther Nucleic Acids. 2016; 5:e349.[41] Schaefer KA, Wu WH, Colgan DF, et al. Unexpected mutations after CRISPR-Cas9 editing in vivo. Nat Methods. 2017;14(6):547-548.[42] Fu Y, Sander JD, Reyon D, et al. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014;32(3):279-284.[43] Hendel A, Bak RO, Clark JT, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol. 2015;33(9):985-989.[44] Lee K, Mackley VA, Rao A, et al. Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering. Elife. 2017;6: e25312.[45] Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520(7546): 186-191.[46] Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016; 351(6268):84-88.[47] Hu JH, Miller SM, Geurts MH, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. 2018;556(7699):57-63.[48] Mandegar MA, Huebsch N, Frolov EB, et al. CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs. Cell Stem Cell. 2016;18(4): 541-553.[49] González F, Zhu Z, Shi ZD, et al. An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell. 2014;15(2):215-226.[50] Paix A, Folkmann A, Goldman DH, et al. Precision genome editing using synthesis-dependent repair of Cas9-induced DNA breaks. Proc Natl Acad Sci U S A. 2017;114(50): E10745-E10754.[51] Zhang JP, Li XL, Li GH, et al. Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage. Genome Biol. 2017;18(1):35.[52] Zhou H, Zhou M, Li D, et al. Whole genome analysis of CRISPR Cas9 sgRNA off-target homologies via an efficient computational algorithm. BMC Genomics. 2017;18(Suppl 9):826.[53] DiGiusto DL, Cannon PM, Holmes MC, et al. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev. 2016;3:16067.[54] Tycko J, Myer VE, Hsu PD. Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity. Mol Cell. 2016; 63(3):355-370.[55] Affiliated Hospital to Academy of Military Medical Sciences. Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances.https://clinicaltrials.gov/ct2/show/NCT03164135?term=stem&cond=crispr&rank=1.2017-05-23/2018-03-25.[56] Chinese University of Hong Kong. Identification of Host Factors of Norvovirus Infections in Mini-GutModel. https://clinicaltrials.gov/ct2/show/NCT03342547?term=stem&cond=crispr&draw=2&rank=2.2017-11-17/2018-03-25[57] Sangamo Therapeutics. Product Pipeline. https://www.sangamo.com/product-pipeline/hemoglobi- nopathies. 2018/2018-03-25[58] EDITAS MEDICINE. Diverse Pipeline Across Range of Diseases. http://www.editasmedicine. com/pipeline. 2017-12-09/2018-03-25[59] Intellia THERAPEUTICS. Pipeline. https://www.intelliatx.com/pipeline/. 2018-02-28/2018-03-25.[60] CRISPR THERAPEUTICS. OUR PIPELINE. http://crisprtx.com/our-programs/our-programs.php. 2018/ 2018-03-25.[61] Duardo-Sanchez A. CRISPR-Cas in Medicinal Chemistry: Applications and Regulatory Concerns. Curr Top Med Chem. 2017;17(30):3308-3315. |
.jpg)
.jpg)
.jpg)